<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the effect of a calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi>, nilvadipine, on cerebral blood flow and oxygen metabolism, we prospectively examined five ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo> patients, with both <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> major cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, using <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography </plain></SENT>
<SENT sid="1" pm="."><plain>The blood pressure showed a significant decrease after 3 months of nilvadipine treatment, the cerebral blood flow in the affected regions showed a significant increase and the oxygen extraction fraction showed a significant decrease </plain></SENT>
<SENT sid="2" pm="."><plain>We conclude that nilvadipine is a safe and effective anti-hypertensive agent for patients with both <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> major cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
</text></document>